Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults

KENILWORTH, N.J.--(BUSINESS WIRE) June 22, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials